FY2026 Earnings Estimate for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Femasys in a research report issued on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.40) for the year, down from their prior estimate of ($0.39). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at $0.12 EPS.

Femasys Price Performance

Femasys stock opened at $1.60 on Monday. Femasys has a one year low of $0.86 and a one year high of $1.84. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The business has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.21. The company has a market cap of $36.64 million, a P/E ratio of -1.98 and a beta of -2.85.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in FEMY. XTX Topco Ltd raised its stake in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Femasys during the 4th quarter worth $25,000. Northern Trust Corp raised its stake in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Femasys during the 4th quarter worth $30,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.